HLA-A and pancreatic adenocarcinoma: Therefore, CRISPR/Cas9 editing was used to introduce DNA encoding either the KRASG12D mutation or HLA-A*11 into the natural locus under the control of the native promoter of a pancreatic adenocarcinoma cell line PSN-1.